Google Button Μake us preferred on Google
A Greek research initiative is seeking to answer one of the most challenging questions in modern neuroscience, opening up a new avenue in the fight against Alzheimer’s disease.

At the center of the research is RSQ-020, a small molecule discovered with the help of an innovative technology platform. In experimental models, the compound restored impaired learning and memory abilities, even after cognitive deficits had already developed.

The discovery resulted from a collaboration between the Alexander Fleming Biomedical Sciences Research Center, the National Hellenic Research Foundation and Greek biotechnology company ResQ Biotech. The research strategy focuses on the Tau protein, whose abnormal accumulation is closely associated with neurodegeneration and cognitive decline in Alzheimer’s disease.

The significance of the findings lies not only in the effects the molecule produced in experimental models, but also in the different approach it takes to an especially challenging biological problem. Rather than simply searching for a substance that binds to a specific site on the protein, the research team developed a technology platform that can identify molecules capable of restoring its normal function inside living cells.

“We cannot say that the experimental animals remembered specific memories they had already lost,” explains Georgios Skretas, director of the Institute of Bio-innovation at the Alexander Fleming Biomedical Sciences Research Center. What the researchers did establish, however, was that a function that had been lost was restored.

As he explained to TA NEA, the fruit fly model used in the research shows a progressive decline in learning and memory abilities when the pathological human Tau protein is expressed. Administration of RSQ-020 began only after these deficits had already appeared.

The distinction

“After treatment, the animals’ performance in learning and memory tests returned to the levels of healthy animals. The results show that the treatment was able to restore a cognitive function that had already been impaired: the animals regained the ability to learn and retain new information.”

The distinction is significant, Skretas said. The findings concern an animal model that reproduces specific aspects of Tau pathology, rather than the full complexity of human Alzheimer’s disease. The results are therefore highly encouraging, but, as he noted, the next critical question is whether they can be replicated in more complex models, with the ultimate goal of testing the approach in humans.

For many years, a large part of Alzheimer’s research focused on beta-amyloid, the protein that forms characteristic deposits in the brains of patients. In recent years, the development and approval of treatments targeting amyloid have marked an important shift in the treatment of the disease, making it possible to slow its progression in some patients with early-stage Alzheimer’s. However, the clinical benefits remain relatively limited, and the need for additional therapeutic strategies is still considerable.

This is where Tau has attracted particular interest.

“Tau is at the center of attention because its abnormal accumulation and, above all, the spread of the resulting pathology throughout the brain are closely linked to neurodegeneration and cognitive decline. Despite its importance, it remains an especially difficult therapeutic target because it does not have a stable three-dimensional structure.”

This makes it harder to develop molecules that can target the protein through conventional pharmacological approaches.

“I do not believe we should see this as a choice between ‘beta-amyloid or Tau.’ Alzheimer’s disease is much more complex than a single protein,” Skretas said.

In his assessment, future treatments may involve combined or sequential interventions targeting different mechanisms and stages of the disease, rather than relying on a single drug. Under such an approach, targeting amyloid and Tau could prove complementary.

The RSQ-020 molecule and its interaction with Tau

One of the most interesting aspects of the research is how RSQ-020 appears to work. According to the findings so far, the molecule interacts directly with Tau and changes the range of conformations the protein can adopt. It appears to favor more compact states, in which regions of the protein that are particularly prone to aggregation become less exposed.

“In simple terms, it does not appear to work like a conventional ‘key’ fitting into a fixed ‘lock.’ Instead, it seems to change the likelihood that Tau will adopt different forms, steering it away from those that favor pathological accumulation,” explains the head of the research project.

The findings are not limited to preventing the formation of new aggregates. The team has also observed indications that RSQ-020 may affect pathological Tau structures that have already formed.

In experiments in which pre-existing aggregates, isolated from the brain tissue of patients, were incubated with the molecule, researchers recorded a significant reduction in insoluble pathological material. They also observed a substantial decrease in its ability to trigger new Tau aggregation in cells.

This observation is important because it suggests that the molecule’s effects may extend beyond preventing the formation of new pathological structures and may also influence pathology that is already established. However, the precise molecular mechanism has not yet been fully clarified. The research team has not mapped a single, specific binding site for RSQ-020, nor does it yet know the molecular fate of all the Tau protein following exposure to the molecule.

Behind the discovery of RSQ-020 is a technology platform intended to change the way new drugs are identified. The method is based on modified bacteria that function as microscopic laboratories for discovering biologically active molecules.

Researchers introduce the human protein they want to study into the bacteria, creating a system that allows them to detect whether the protein is in a problematic state. At the same time, the bacteria produce vast libraries of different small molecules, mainly cyclic peptides.

“Each bacterial cell essentially functions as a separate miniature experiment: it produces a different molecule and simultaneously tests whether that molecule can correct the problem,” Skretas explains.

“We have designed the system so that when a functional molecule is produced inside a cell, the bacterium ‘announces’ it with a bright green light. This allows us to identify the few cells containing an active molecule within a vast population of cells.”

The difference from conventional drug discovery is substantial. Instead of beginning by searching for the molecule that binds most effectively to a protein, this platform sets out to identify which molecule actually works inside a living cell.

“This approach is particularly valuable for proteins such as Tau, which do not have a stable structure and are difficult to target using the logic of binding to a specific site. For us, RSQ-020 is also an initial proof of what this platform can produce. Our greater ambition is to create a reusable method for discovering drugs that target proteins considered extremely difficult to address.”

The three-year horizon and the critical next steps

When could RSQ-020 reach its first clinical trials in humans? The head of the research project is cautiously optimistic, emphasizing that this is a target, not a certainty.

If studies in mice confirm the effectiveness observed so far, if sufficient exposure of the brain can be achieved through safe, repeated administration, and if the remaining stages of preclinical development are completed successfully, a timeline of approximately three years to gather the data needed to support the move toward initial clinical trials is considered ambitious but feasible.

Until then, several critical steps remain, Skretas said. These include efficacy studies in mammals, a full pharmacokinetic assessment, determining the appropriate dose, safety testing following repeated administration, developing a manufacturing process suitable for pharmaceutical use, selecting the appropriate pharmaceutical formulation and completing the required regulatory dossier.

“At this stage, however, developing a drug is no longer solely a scientific issue. It is also a question of resources and speed of execution. With sufficient funding, several of these activities can proceed in parallel rather than sequentially, significantly reducing the time needed to answer the critical question: Can RSQ-020 become a drug for humans?”

Prospects

The potential applications extend beyond Alzheimer’s disease. The same technological approach was initially developed to target amyotrophic lateral sclerosis (ALS) and the SOD1 protein, leading to the approval of the first treatment.

“This highly positive development for patients led us to ask where our technology could offer even greater added value and address a major unmet medical need.”

The research team subsequently turned its attention to Tau.

“What is important, however, is that our technology can also be applied to other diseases in which the misfolding or accumulation of a protein plays a central role — for example, alpha-synuclein in Parkinson’s disease.”

Skretas clarifies, however, that this is not a technology that can automatically be applied to every condition, but rather a reusable approach to drug discovery.

For Skretas, the challenge is no longer proving that internationally competitive scientific research can be conducted in Greece. That has already been demonstrated. The difficult part is ensuring the conditions are in place for a discovery originating in Greek laboratories to develop into a full-fledged drug development program with prospects extending beyond the country’s borders.

“In our case, the technology was developed in Greek research laboratories, supported to a large extent by highly competitive European funding, and led to the creation of ResQ Biotech precisely to make this transition possible. Much greater investment is now required,” he said.

He concluded: “For us, securing the resources that will allow the next preclinical studies to proceed in parallel and at the necessary pace could determine how quickly we reach the next stage. The major challenge is not simply to generate important discoveries in Greece and Europe. It is also to create the conditions that allow the best of them to develop here into internationally competitive companies and, ultimately, into new medicines that reach patients.”